ClinicalTrials.gg
RecruitingNCT05870800NICERUpdated May 25, 2025

Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER

A Phase 2 interventional study of Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2 and Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2 in Stage I Colon Cancer, Stage II Colon Cancer and Stage III Colon Cancer, sponsored by Baylor College of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Baylor College of Medicine · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies testing oxaliplatin in Colonic Neoplasms — 4 open to participants now, 9 under way, 4 of them phase 3. Oxaliplatin · Colonic Neoplasms.

Planned enrollment
61st of 88
28 · median 54
Started
2025
the only one that year
Phase 2
46 of 111
3 open now
Registered
109th of 111
by date

Among the 111 studies testing oxaliplatin in Colonic Neoplasms, this one is the 61st largest by planned enrollment of the 88 interventional ones that give a count, is the only one that started in 2025, is one of 46 in phase 2, and was the 109th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

4 of the 111 studies testing oxaliplatin in Colonic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing oxaliplatin in Colonic Neoplasms, or all of them as a file.
02

Study summary

This is a Phase II open-label trial of neoadjuvant immunochemotherapy with Atezolizumab and CAPOX followed by surgery and potentially adjuvant chemotherapy for patients with localized resectable pMMR adenocarcinoma of the colon with a target accrual of 28 patients. The investigators will explore if appropriately timed neoadjuvant CAPOX with anti-PD-L1 mAb (Atezolizumab) can be administered safely and feasibly, and that this combination will lead to improved clinical response associated with enhanced numbers of immune cells in surgically resected colon tumors. Patients will receive 4 cycles of atezolizumab in combination with 4 cycles of CAPOX (atezolizumab will be administered prior to chemotherapy) before standard of care surgical resection. Following surgery, patients still considered to be at high-risk of recurrence (per SOC guidelines) will receive further adjuvant chemotherapy (mFOLFOX6 or CAPOX), based on the discretion of the treating oncologist/investigator. Circulating tumor DNA (ctDNA) dynamic change status will be analyzed through collection of blood samples throughout different stages of the patient's neoadjuvant treatment regimen (baseline, pre-neoadjuvant therapy, mid-neoadjuvant, post-neoadjuvant therapy, and during postoperative period) as a marker of early read on efficacy.

The end of the study for each patient enrolled will be at the 6 month postoperative visit.

On Study Protocol: Patients will be followed up for an efficacy follow-up phase during the first 6 months after surgery (week 2 \& months 3, 6 visits). All assessments beyond the 6 month visit will be performed under standard of care surveillance office visits.

Off Study Protocol: Thereafter they will enter a survival follow-up phase per standard of care protocols. Patients will be seen every 6 months starting at month 12 until month 36. All collection of research-specific assessments including whole blood, stool collection and quality of life questionnaires will be optional beyond the 6 month postop visit (months 12-36).

Read the detailed description

This is a Phase II open-label trial of neoadjuvant immunochemotherapy with Atezolizumab + CAPOX chemotherapy followed by surgery and adjuvant chemotherapy (only for high-risk patients) for patients with localized resectable pMMR adenocarcinoma of the colon with a target accrual of 28 patients. The investigational medicinal product (IMP) for this study is atezolizumab. Neoadjuvant CAPOX chemotherapy regimen or category (including rescue medications, premedications), in addition to adjuvant chemotherapy regimens (mFOLFOX6 and CAPOX) are considered non investigational medicinal products (NIMPs).

Please note all RESEARCH ONLY PROCEDURES ARE MARKED WITH A " * " BASELINE VISIT

Once eligibility of potential subjects is confirmed and consent is obtained eligible subjects will undergo the following procedures:

  1. Informed Consent *
  2. History \& Physical exam
  3. Vital Signs
  4. Assessment of concomitant medications
  5. Performance Status (ECOG)
  6. PRO/QOL assessments (Research)*
  7. Eligibility Assessment*
  8. Routine Imaging and Laboratory
  9. Blood collection for ctDNA analysis (mandatory) and biobanking (optional)*
  10. Stool collection*
  11. Urine pregnancy test

NEOADJUVANT THERAPY (RESEARCH) After baseline assessments and eligibility has been confirmed, patients will receive 4 cycles of neoadjuvant immunochemotherapy for a total of 12 weeks. Therapy consists of Atezolizumab in combination with CAPOX (capecitabine + oxaliplatin) before standard-of-care surgical resection. Each cycle of neoadjuvant therapy is 3 weeks. After completion of neoadjuvant therapy, patients will be evaluated during a presurgical evaluation visit for follow-up of any side effects that could potentially arise from therapy and to determine readiness for surgical removal of the tumor (staging evaluation and assessment of response). During this evaluation visit repeat imaging (CT scan or MRI) will be obtained between 2-8 weeks following completion of neoadjuvant therapy. During each cycle the following assessments will be evaluated*:

  1. History \& Physical exam *
  2. Vital Signs *
  3. Adverse event assessment*
  4. Assessment of concomitant medications *
  5. Administration of neoadjuvant therapy with Aztezoluzumab and CAPOX chemotherapy*
  6. Routine laboratory assessments*
  7. Blood collection for ctDNA analysis (mandatory) and biobanking (optional) during mid-therapy and at conclusion of therapy*
  8. Stool collection (after each cycle)*
  9. Imaging for disease restaging and therapy response (CT or MRI) of abdomen and pelvis will be obtained after neoadjuvant therapy (2-4 weeks after neoadjuvant therapy)

    • *All assessments for this visit are considered research.

SURGERY Surgical removal of the tumor will be performed per standard-of-care practices. Tumor sample will be obtained per standard of care procedure and will be used after final diagnosis by pathology.

POSTOPERATIVE FOLLOW-UP AND ADJUVANT CHEMOTHERAPY Efficacy Follow-up phase (week 2, month 3 \& month 6) Long-term (survival) Follow-up phase (Months 12-36)

Following surgery, patients will enter an efficacy follow-up phase (initial 6 months) and a long-term (survival) follow-up phase (months 12-36). Patients still considered to be at high risk of recurrence (per NCCN guidelines) will receive further adjuvant chemotherapy based on protocol and the discretion of the treating oncologist/investigator.

EFFICACY FOLLOW-UP PHASE ( Week 2 postop and Months 3, 6) Patients will be followed up for an efficacy follow-up phase during first 2 weeks postop and months 3 and 6 and will complete the following assessments:

  1. History \& Physical exam
  2. Vital Signs
  3. Adverse event assessment*
  4. Assessment of concomitant medications
  5. Quality of life assessments (satisfaction survey at week 2 and month 3 only)*
  6. Vital status update*
  7. Assessment of adjuvant therapy*
  8. Blood collection for ctDNA analysis and biobanking* (ctDNA blood draw only at week 2 visit)
  9. Stool collection *
  10. Adjuvant chemotherapy with standard of care chemotherapy (ONLY FOR HIGH-RISK PATIENTS)
  11. Laboratory analysis (CEA,CBC \& Chemistry panel)(3 \& 6 months only)
  12. Standard of care imaging (6 months only)

LONG TERM/ SURVIVAL FOLLOW-UP PHASE Patients will be followed up for an long-term (survival) follow-up phase during months 12, 18, 24, 30, and 36 and will complete the following assessments:

  1. History \& Physical exam
  2. Vital Signs
  3. Adverse event assessment*
  4. Assessment of concomitant medications
  5. Quality of life assessments*
  6. Vital status update*
  7. Blood collection for biobanking (these samples are optional) *
  8. Stool collection *
  9. Standard of care imaging

Research procedures:

  1. Blood and stool samples will be collected for ctDNA analysis (mandatory) and for banking (optional) at baseline and throughout different stages of the study for future exploratory analysis. The optional blood samples will be stored at Baylor College of Medicine main campus in the ABBR (Alkek Building for Biomedical Research) laboratory and kept for up to 10 years. The purpose of biobanking these samples is for future exploratory research analyses based on future available funding. Stool sample collection kits will be provided to participating subjects which they will be shipping back to our site and collected at several timepoints for storage and future use. In the future stool samples may be used for metabolomic and proteomic profiling. (Costs of shipping back stool kits will be covered by site/sponsor).
  2. Quality of life (QOL) outcomes will be obtained through patient- reported outcome (PRO) questionnaires (approx. duration: \~10-20 min per visit) PRO data will be collected through use of the following instruments: MD Anderson Symptom Inventory (MDASI), QLQ C30, and a satisfaction survey. All patients will complete the MDASI, QLQ-C30, and questionnaires at the following timepoints: baseline, after neoadjuvant therapy completion, postoperatively on week 2, months 3, 6, 12, 18, 24, 30, 36. The satisfaction survey will be only collected at week 2 and month 3.
  3. Banking procedures: A proper IRB submission will be submitted for request of historic sample controls to previously biobanked specimens within Baylor's biobanks. Historic samples will be deidentified and will be used for comparison. An attempt will be made to match demographics and tumor site but this comparison is going to be used only as an exploratory endpoint.
  4. Storage of Data: Each patient will have their own research binder in which research data will be collected. Each subject will be assigned a unique study number ID and will be used throughout the patient's participation. No personal data will be used to identify patients, only the study ID will be used for confidentiality purposes. Data will be captured manually in the patient's binder and electronically in Oncore using study ID number only. Subject binder will be stored in a locked cabinet on the 7th floor at the McNair campus. Only authorized personnel will have access to patient's binder. Information from medical chart that will be used includes: demographic data, concomitant medications, vital signs, medical history, laboratory results, imaging results, notes from office visits, surgery notes, operative notes, progress notes, pathology reports. No information will be shared with any third parties.
03

Conditions studied

  • Stage I Colon Cancer
  • Stage II Colon Cancer
  • Stage III Colon Cancer

Browse trials for

Keywords

  • Non-metastatic resectable colon cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form
  • Age ≥18 years at time of signing Informed Consent Form
  • Ability to comply with the study protocol
  • MSS or pMMR tumor determined by local CLIA-certified PCR or IHC testing respectively.
  • or cytologically confirmed resectable non- adenocarcinoma of the colon.
  • The distal extent of the tumor must be ≥12 cm from the anal verge on pre-surgical endoscopy and/or imaging (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation). If the patient did not undergo a pre-surgical endoscopy, then the distal extent of the tumor must be ≥12 cm from the anal verge as determined by surgical examination or pre-operative imaging.
  • One or more of the following high-risk features:

    • High CEA levels (>5 ng/ml in non-smoker patients , >10ng/ml in smoker patients)
    • Low Lymphocyte-to-monocyte Ratio (\<2.38)
    • Poor grade of tumor differentiation
    • Evidence of Lymphovascular Invasion
    • Evidence of Perineural Invasion
    • CT evidence of T3 orT4 disease w/ ≥4 cm tumor longitudinal diameter
    • CT evidence of regional lymphadenopathy
  • (ECOG) Performance Status of 0-1
  • Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:

    • ≥ 1.5 x 10*9/L (1500/mL) without granulocyte colony-stimulating factor support
    • Lymphocyte count ≥ 0.5 x 10*9/L (500/µL)
    • count ≥100 x 10*9/L (100,000/µL) without transfusion
    • ≥ 9 g/L (9 g/dL) Patients may be transfused to meet this criterion.
    • , ALT, and alkaline phosphatase (ALP) ≤ 2.5 x (ULN)
    • Serum ≤ 1.5 x ULN with the following exception:

Patients with known Gilbert disease: serum bilirubin ≤ 3 x ULN

  • Serum creatinine ≤1.5 x ULN or ≥ 50 mL/min (calculated using the Cockcroft-Gault formula)
  • Serum albumin ≥ 25 g/L (2.5 g/dL)
  • For patients not receiving therapeutic anticoagulation: or aPTT ≤ 1.5 x ULN

    • For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
    • Negative surface antigen (HBsAg) test at screening
    • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening The HCV RNA test must be performed for patients who have a positive HCV antibody test.
    • Negative test at screening
    • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, and agreement to refrain from donating eggs, as defined below:

Women must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for 5 months after the final dose of atezolizumab and for 6 months following any of the chemotherapy regimens (if applicable) after the final dose of mFOLFOX6 or CAPEOX.Women must refrain from donating eggs during this same period.

A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fallopian tubes and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Per this definition, a woman with a tubal ligation is considered to be of childbearing potential. The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.

Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.

  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \<1% per year during the treatment period and for 5 months after the final dose of any chemotherapy regimen. Men must refrain from donating sperm during this same period.

With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 5 months after any of the chemotherapy regimens to avoid exposing the embryo.

The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic, untreated, or any site actively progressing disease.
  • History of
  • Uncontrolled tumor-related pain Patients requiring pain medication must be on a stable regimen at study entry. Presence of any metastatic effusion (pleural, pericardial, ascites)
  • Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > )
  • Active or history of disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis (see Appendix 11 for a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions:

Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.

Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.

Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

  • Rash must cover \< 10% of body surface area
  • Disease is well controlled at baseline and requires only low-potency topical
  • There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

    • Active tuberculosis
    • Significant cardiovascular disease (such as Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
    • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
    • History of other than colon adenocarcinoma within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, Stage I uterine cancer or colonic polyps
    • Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety
    • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or exacerbation) are eligible for the study.
    • Prior allogeneic stem cell or solid organ transplantation
    • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
    • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
    • Current treatment with anti-viral therapy for
    • Synchronous primary rectal and/ or colon cancers or history of prior invasive colon malignancy, regardless of disease-free interval.
    • Treatment with investigational therapy within 28 days prior to initiation of study treatment
    • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies
    • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
    • Treatment with systemic medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF- agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.

Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.

  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products or to any component of the atezolizumab formulation
  • Known allergy or hypersensitivity to any component of the CAPOX or mFOLFOX6 chemotherapy formulations
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months for Atezolizumab and 6 months for any chemotherapy regimen after the final dose of study treatment Women of must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Therapy Arm

    Subjects will receive 4 cycles of neoadjuvant atezolizumab in combination with 4 cycles of CAPOX before standard of care surgical resection. After surgery, patients who are still considered high risk for recurrence (per the treating medical oncologist) will be offered adjuvant therapy.

    Drug: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2 · Drug: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2 · Drug: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2

Interventions

  • DrugTecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2

    Drug page: AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)

    Also known as: Neoadjuvant Chemoimmunotherapy

  • DrugOxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2

    Drug page: OxaliplatinStudies of OxaliplatinOxaliplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)

    Also known as: mFOLFOX6

  • DrugOxaliplatin 130mg/m2 + Capecitabine 1000mg/m2

    Drug page: OxaliplatinStudies of OxaliplatinOxaliplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)

    Also known as: CAPOX

06

What researchers measure

Primary outcomes

  1. Determine the rate of tumor regression grade 1 (<10% viable cancer cells) to neoadjuvant immunotherapy and chemotherapy in resectable (non-metastatic) pMMR colon cancer, assessed in the resection specimen.

    The primary outcome will be evaluated using the modified Ryan scoring system to score tumor regression grades (TRGs) in the surgical specimen. Scores will be assessed by dedicated study pathologists. Success is defined as TRG-0 or TRG-1(\<10% viable cancer cells). Efficacy-evaluable participants who do not go to surgery, perhaps due to clinical progression, will be counted as a failure.

    Time frame: 3-5 months

Secondary outcomes

  1. Complete pathologic response (TRG-0) to neoadjuvant immunochemotherapy or not.

    The investigators will estimate the rate of tumor regression grade (TRG) 0/1 and corresponding exact 95% confidence interval (Wilson method) in the 'efficacy' population. The rate will be compared to the null value of 1% using an exact binomial test with a 5% one-sided significance level. With N=25 efficacy evaluable participants, the investigators will need to see at least 2 grade 0/1 tumor regressions in order to reject the null hypothesis.

    Time frame: 36 months

  2. R0 resection and number of lymph nodes harvested after neoadjuvant combination CAPOX / Atezolizumab

    R0 resection rate will be summarized as described for the primary endpoint.

    Time frame: 3-4 months

  3. Utilize dynamic changes in ctDNA as an early assessment tool on therapy efficacy. Analysis of ctDNA status to evaluate incidence and changes in surrogate ctDNA biomarker presence.

    CtDNA dynamic changes as an early assessment on efficacy. Analysis of ctDNA status (pre-neoadjuvant therapy, mid-neoadjuvant therapy, post- neoadjuvant therapy and postoperative) correlating ctDNA with outcomes and to evaluate incidence and changes in surrogate ctDNA biomarker presence.

    Time frame: 36 months

  4. Occurrence of any grade 3 or greater adverse events possibly, probably or definitively related to the neoadjuvant CAPOX / Atezolizumab combination

    This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0 for toxicity and Serious Adverse Event reporting, with the exception of skin- or nail-related toxicities, which will be graded using CTCAE version 5.0 with modifications. Treatment emergent AE's (grade 3 or greater), will be tabulated with counts of AE's at each grade, as well as counts of participants experiencing any grade 3 or greater treatment emergent AE.

    Time frame: 3-12 months

  5. Quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    QoL scores and patient satisfaction results will be computed using standard guidelines and displayed graphically as spaghetti plots. QLQ-C30 scores range from 0 to 100, with higher scores indicating higher/better functioning and higher/better global health status/QoL but lower/worse symptom burden.

    Time frame: 36 months

  6. Quality of life as assessed by MD Anderson Symptom Inventory (MDASI)

    QoL scores and patient satisfaction results will be computed using standard guidelines and displayed graphically as spaghetti plots. The M. D. Anderson Symptom Inventory (MDASI) is a brief, patient-reported outcome measure of the impact and severity of 13 cancer-related symptoms that are common across all cancer types. The MDASI score goes from 0 (symptom has not been present) to 10 (the symptom is as worse as it could be) for each item. Higher score means worse outcome.

    Time frame: 36 months

  7. Delay in surgery after neoadjuvant therapy by more than 12 weeks (84 days) or no

    Complete surgical resection rates (R0) will be monitored in these patients and if the R0 resection rate is numerically lower than the historical average of \~73% noted in the literature, further analysis of these cases would be performed to ensure that this was not attributed to the delay caused by neoadjuvant therapy.

    Time frame: 3-24 months

  8. Rate of treatment acceptance measured by a patient satisfaction questionnaire (PSQ) result at specified time points.

    An in-house patient satisfaction questionnaire (PSQ) results will be computed using standard guidelines and displayed graphically as spaghetti plots. The patient satisfaction questionnaire is a brief, in house, patient satisfaction questionnaire to assess the rate of patient satisfaction, tolerance and acceptance of neoadjuvant treatment used during the study. It includes a brief 10-question assessment and score goes from 0 (not satisfied at all) to 10 (very satisfied).

    Time frame: 6-12 months

  9. Overall Survival (OS)- Post-surgery times to event

    Post-surgery times to event (OS) will be measured in months throughout the duration of the study (36 months). Overall survival (OS) is the time from surgery to death from any cause, regardless of disease recurrence (safety population). OS will be summarized by Kaplan-Meier curves, with estimates of median time to event (95% CI by log-log transform), and selected time-specific survival rates (95% CI).

    Time frame: 36 months

  10. Relapse-free survival (RFS)- Post-surgery times to event

    Post-surgery times to event (RFS) will be measured in months throughout the duration of the study (36 months). Relapse-free survival (RFS) is defined as the time from surgery to any event, where an "event" is defined first radiographical or pathological evidence of recurrence of disease (excluding second primary cancers) or death from any cause, whichever comes first. RFS will be summarized by Kaplan-Meier curves, with estimates of median time to event (95% CI by log-log transform), and selected time-specific survival rates (95% CI).

    Time frame: 36 months

  11. Time to first recurrence (TTR) -Post-surgery times to event

    Post-surgery times to event (TTR) will be measured in months throughout the duration of the study (36 months). Time to first recurrence (TTR) is the time from surgery to first radiological or pathological evidence of recurrence, excluding second primary cancers. TTR will be summarized by Kaplan-Meier curves, with estimates of median time to event (95% CI by log-log transform), and selected time-specific survival rates (95% CI).

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
    • Hector J Garcia-Chavez, MD · Contacthector.garcia-chavez@bcm.edu · 713-798-6419
    • Amy Wood · Contactamy.wood@bcm.edu
    • Atif Iqbal, MD · Principal investigator
    • Shalini Makawita, MD · Principal investigator
    • Benjamin Musher, MD · Sub investigator
    • Yesenia Rojas-Khalil, MD · Sub investigator
    • Tannaz Armaghany, MD · Sub investigator
    • Ernest R. Camp, MD · Sub investigator
    • Karen Riggins, MD · Sub investigator
    • Punam Parikh-Amin, MD · Sub investigator
    • Eric Silberfein, MD · Sub investigator
    • Cary Hsu, MD · Sub investigator
    • Carlos Farinas, MD · Sub investigator
    • Shilpa Jain, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Sep 2026, 14 months later.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 14 months is below that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
May 23, 2023
StartEst.
Jun 15, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Jan 1, 2028
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05870800
Collaborators
Genentech, Inc.
Responsible party
Atif Iqbal (Associate Professor, Baylor College of Medicine) — Principal investigator
First posted
May 23, 2023
Start date
Jun 15, 2025 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
May 25, 2025

Study contacts

Hector J Garcia-Chavez, MD
Contact
hector.garcia-chavez@bcm.edu
713-798-6419
Atif Iqbal, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Oxaliplatin

Start the discussion